FindTrial
Sign In

To study the effect of nebulized dexmedetomidine in different doses during bronchoscopic procedure

Effect of different doses of dexmedetomidine as adjuvant to lignocaine nebulization: A comparative study during awake flexible fiberoptic bronchoscopy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/10/021629
Enrollment
90
Registered
2019-10-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J989- Respiratory disorder, unspecified

Interventions

Intervention1: Dexmedetomidine nebulization (0.5mcg/kg) during bronchoscopy: Group I Patient will be nebulized with mixture of 4% lignocaine 4ml and dexmedetomidine 0.5µg/kg by using ultrasonic nebu

Sponsors

AIIMS Patna
Lead Sponsor
AIIMS Patna
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. ASA I/II 2. Scheduled for elective bronchoscopy procedure (Diagnostic & therapeutic)

Exclusion criteria

Exclusion criteria: 1. Unconscious and uncooperative patients 2. Intubated patient on ventilator, patient need general anaesthesia, 3. Patient on oxygen 4. Allergic to LA, dexmedetomidine 5. Asthmatics 6. Epileptics 7. Coagulation abnormalities 8. Haemodynamic instability, bradyarrhythmias

Design outcomes

Primary

MeasureTime frame
Cough severity scoreTimepoint: At 0 min (base line), 5 min, 10 min, 15 min, 20 min (during insertion of bronchoscope), 25min, 30 min , 45 min and at 60 min.—

Secondary

MeasureTime frame
Patient comfortTimepoint: At 0 min (base line), 5 min, 10 min, 15 min, 20 min (during insertion of bronchoscope), 25min, 30 min , 45 min and at 60 min.—

Countries

India

Contacts

Public ContactDr Amarjeet Kumar

AIIMS Patna

amarjeetdmch@gmail.com9570890646

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026